Newsroom

In a major milestone in the search for a cure for HIV/AIDS, a breakthrough gene-editing therapy for HIV infection now being tested in clinical trials has been administered to a human with HIV for the first time. The trial, designed to evaluate the safety and efficacy of EBT-101, a one-of-a-kind gene-editing treatment, is the product of a collaborative effort between researchers at the Lewis Katz School of Medicine at Temple University and Excision BioTherapeutics, Inc. The launch of the EBT-101 Phase 1/2 clinical trial was made possible by research led by Kamel Khalili, PhD, Laura H. Carnell Professor and Chair of the Department of Microbiology, Immunology, and Inflammation; Director of the Center for Neurovirology and Gene Editing; and Director of the Comprehensive NeuroAIDS Center, and Tricia H. Burdo, PhD, Professor and Vice Chair in the Department of Microbiology, Immunology, and Inflammation at the Katz School of Medicine. 6ABC and Scienmag highlighted the news.

Researchers at the Lewis Katz School of Medicine at Temple University announced in a Late-Breaking Innovation Session at the 2022 Transcatheter Cardiovascular Therapeutics conference that the BASHIR™ Endovascular Catheter significantly reduces the size of blood clots lodged in pulmonary arteries, leading to improvement in heart function in patients with pulmonary embolism. The breakthrough is also described in a report published in the Journal of the American College of Cardiology: Cardiovascular Interventions. Riyaz Bashir, MD, FACC, Professor of Medicine at the Katz School of Medicine and Director of Vascular and Endovascular Medicine at Temple University Hospital, is the co-inventor of the catheter. Dr. Bashir conducted a video interview with Clinical Trial Results about the catheter and the RESCUE trial, a clinical study designed to evaluate the safety and efficacy of the catheter as a novel therapy for pulmonary embolism. The American College of Cardiology, Scienmag and the Science Times also highlighted the news. Parth Rali, MD, Associate Professor of Thoracic Medicine and Surgery at the Lewis Katz School of Medicine and Director of the Temple University Health System Pulmonary Embolism Response Team (PERT), is the local principal investigator on the RESCUE trial. Vladimir Lakhter, DO, Assistant Professor of Medicine at the Lewis Katz School of Medicine and an interventional cardiologist, is also involved in the RESCUE trial.

A Philadelphia Inquirer article focused on how area medical schools, including the Lewis Katz School of Medicine at Temple University, are utilizing standardized patients in medical education. The Inquirer article highlighted a new grant that Temple received to develop an educational program to promote sensitive and equitable care for transgender and nonbinary people in Philadelphia. Jamie Garfield, MD, Professor of Thoracic Medicine and Surgery and Core Clinical Educator at the Katz School of Medicine and Director of Quality and Improvement and Patient Safety, Core Clinical Faculty, Internal Medicine Residency, at Temple University Hospital, is the principal investigator on the grant and spoke with the Inquirer. Denise Salerno, MD, FAAP, Associate Dean of Undergraduate Medical Education and Longitudinal Curricular Threads and Professor of Clinical Pediatrics at the Katz School of Medicine, and David A. Wald, DO, FACOEP, Interim Assistant Dean of Phase 3 and Assistant Dean of Clinical Simulation and Professor of Emergency Medicine at the Katz School of Medicine, were also interviewed.